Literature DB >> 18490721

Late expression of granulysin by microbicidal CD4+ T cells requires PI3K- and STAT5-dependent expression of IL-2Rbeta that is defective in HIV-infected patients.

Chun Fu Zheng1, Gareth J Jones, Meiqing Shi, Jeremy C D Wiseman, Kaleb J Marr, Byron M Berenger, Shaunna M Huston, M John Gill, Alan M Krensky, Paul Kubes, Christopher H Mody.   

Abstract

Granulysin is a cytolytic effector molecule used by lymphocytes to kill tumor and microbial cells. Regulation of granulysin production is complex. A significant delay (5 days) following stimulation of CD4(+) T cells with IL-2 occurs before granulysin is produced. Unfortunately, the mechanisms responsible for this delay are unknown. We have recently demonstrated that granulysin-mediated killing of Cryptococcus neoformans by CD4(+) T cells is defective during HIV infection. This is because CD4(+) T cells from HIV-infected patients fail to produce granulysin in response to IL-2 activation. The present studies examined the mechanism of delayed production of granulysin and the mechanism of the defect in HIV patients. We demonstrate that IL-2 initially requires both STAT5 and PI3K activation to increase expression of IL-2Rbeta, produce granulysin, and kill C. neoformans. The increased expression of IL-2Rbeta precedes granulysin, and preventing the increased expression of IL-2Rbeta using small interfering RNA knockdown abrogates granulysin expression. Moreover, following the increased expression of IL-2Rbeta, blocking subsequent signaling by IL-2 using IL-2Rbeta-specific blocking Abs abrogates expression of granulysin. Finally, CD4(+) T cells from HIV-infected patients, who are defective in both STAT5 and PI3K signaling, fail to express IL-2Rbeta and fail to produce granulysin. These results suggest that IL-2 signals via PI3K and STAT5 to increase expression of IL-2Rbeta, which in turn is required for production of granulysin. These results provide a mechanism to explain the "late" production of granulysin during normal T cell responses, as well as for defective granulysin production by CD4(+) T cells in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490721      PMCID: PMC2661617          DOI: 10.4049/jimmunol.180.11.7221

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  64 in total

1.  PI 3-K and T-cell activation: limitations of T-leukemic cell lines as signaling models.

Authors:  E Astoul; C Edmunds; D A Cantrell; S G Ward
Journal:  Trends Immunol       Date:  2001-09       Impact factor: 16.687

Review 2.  PI3K in lymphocyte development, differentiation and activation.

Authors:  Klaus Okkenhaug; Bart Vanhaesebroeck
Journal:  Nat Rev Immunol       Date:  2003-04       Impact factor: 53.106

Review 3.  Alternate signalling pathways from the interleukin-2 receptor.

Authors:  Jonathan M Ellery; Peter J Nicholls
Journal:  Cytokine Growth Factor Rev       Date:  2002-02       Impact factor: 7.638

4.  Cloning of the gamma chain of the human IL-2 receptor.

Authors:  T Takeshita; H Asao; K Ohtani; N Ishii; S Kumaki; N Tanaka; H Munakata; M Nakamura; K Sugamura
Journal:  Science       Date:  1992-07-17       Impact factor: 47.728

5.  Phosphatidylinositol 3-kinase potentiates, but does not trigger, T cell proliferation mediated by the IL-2 receptor.

Authors:  J J Moon; B H Nelson
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

6.  CD4(+) and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism.

Authors:  D H Canaday; R J Wilkinson; Q Li; C V Harding; R F Silver; W H Boom
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

7.  Human immunodeficiency virus-1 envelope glycoproteins and anti-CD4 antibodies inhibit interleukin-2-induced Jak/STAT signalling in human CD4 T lymphocytes.

Authors:  M Kryworuchko; V Pasquier; J Thèze
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

8.  Phenotypic and functional characterization of human lymphocytes activated by interleukin-2 to directly inhibit growth of Cryptococcus neoformans in vitro.

Authors:  S M Levitz; M P Dupont
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

9.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).

Authors:  C J Vlahos; W F Matter; K Y Hui; R F Brown
Journal:  J Biol Chem       Date:  1994-02-18       Impact factor: 5.157

10.  Characterization of the human interleukin-2 receptor beta-chain gene promoter: regulation of promoter activity by ets gene products.

Authors:  J X Lin; N K Bhat; S John; W S Queale; W J Leonard
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

View more
  8 in total

1.  Gamma(c) deficiency precludes CD8+ T cell memory despite formation of potent T cell effectors.

Authors:  Hélène Decaluwe; Morgan Taillardet; Erwan Corcuff; Ivana Munitic; Helen K W Law; Benedita Rocha; Yves Rivière; James P Di Santo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

Review 2.  Cryptococcal interactions with the host immune system.

Authors:  Kerstin Voelz; Robin C May
Journal:  Eukaryot Cell       Date:  2010-04-09

3.  Granulysin production and anticryptococcal activity is dependent upon a far upstream enhancer that binds STAT5 in human peripheral blood CD4+ T cells.

Authors:  Junji Xing; Fuqing Wu; Shuai Wang; Alan M Krensky; Christopher H Mody; Chunfu Zheng
Journal:  J Immunol       Date:  2010-10-01       Impact factor: 5.422

Review 4.  Direct microbicidal activity of cytotoxic T-lymphocytes.

Authors:  Paul Oykhman; Christopher H Mody
Journal:  J Biomed Biotechnol       Date:  2010-06-23

Review 5.  The Dynamic Interface of Viruses with STATs.

Authors:  Angela R Harrison; Gregory W Moseley
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

6.  Novel biomarker combination improves the diagnosis of serious bacterial infections in Malawian children.

Authors:  Adam D Irwin; Fiona Marriage; Limangeni A Mankhambo; Graham Jeffers; Ruwanthi Kolamunnage-Dona; Malcolm Guiver; Brigitte Denis; Elizabeth M Molyneux; Malcolm E Molyneux; Philip J Day; Enitan D Carrol
Journal:  BMC Med Genomics       Date:  2012-05-04       Impact factor: 3.063

Review 7.  Cytotoxic CD4 T Cells-Friend or Foe during Viral Infection?

Authors:  Jennifer A Juno; David van Bockel; Stephen J Kent; Anthony D Kelleher; John J Zaunders; C Mee Ling Munier
Journal:  Front Immunol       Date:  2017-01-23       Impact factor: 7.561

8.  Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation.

Authors:  Alberto Bosque; Kyle A Nilson; Amanda B Macedo; Adam M Spivak; Nancie M Archin; Ryan M Van Wagoner; Laura J Martins; Camille L Novis; Matthew A Szaniawski; Chris M Ireland; David M Margolis; David H Price; Vicente Planelles
Journal:  Cell Rep       Date:  2017-01-31       Impact factor: 9.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.